Drug research

Dacarbazine

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as DIC; DTIC; DTIC-Dome; Imidazole Carboxamide

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332	IDEAYA Biosciences	Phase 2, Phase 3	Active not recruiting	2027-01-15Estimated
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067	ERAS	Phase 3	Active not recruiting	2028-04Estimated
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392	Immunocore Ltd	Phase 2	Completed	2020-10-13Actual
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)NCT05269355	PTC Therapeutics	Phase 2, Phase 3	Terminated	2024-06-17Actual

IDEAYA BiosciencesActive not recruitingPrimary completion: 2027-01-15 · Estimated

Trial details

ERASActive not recruitingPrimary completion: 2028-04 · Estimated

Trial details

Immunocore LtdCompletedPrimary completion: 2020-10-13 · Actual

Trial details

PTC TherapeuticsTerminatedPrimary completion: 2024-06-17 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.